Akt1

Akt1 Overview

English NameSerine/threonine-protein kinase AKT1Approved Drugs1
Drugs in Clinical Trials24Target SynonymEC:2.7.11.1,EC 2.7.11,Proto-oncogene c-Akt,Protein kinase B,RAC,RAC-PK-alpha,PKB alpha,RAC-alpha serine/threonine-protein kinase,AKT1,AKT Serine/Threonine Kinase 1,V-Akt Murine Thymoma Viral Oncogene Homolog 1,Protein Kinase B Alpha,PKB,V-Akt Murine Thymoma Viral Oncogene-Like Protein 1,Serine-Threonine Protein Kinase,Rac Protein Kinase Alpha,EC 2.7.11.1,PKB-ALPHA,RAC-ALPHA,AKT1m,PRKBA,CWS6,AKT
Highest Development StageApproved
English NameSerine/threonine-protein kinase AKT1
Target SynonymEC:2.7.11.1,EC 2.7.11,Proto-oncogene c-Akt,Protein kinase B,RAC,RAC-PK-alpha,PKB alpha,RAC-alpha serine/threonine-protein kinase,AKT1,AKT Serine/Threonine Kinase 1,V-Akt Murine Thymoma Viral Oncogene Homolog 1,Protein Kinase B Alpha,PKB,V-Akt Murine Thymoma Viral Oncogene-Like Protein 1,Serine-Threonine Protein Kinase,Rac Protein Kinase Alpha,EC 2.7.11.1,PKB-ALPHA,RAC-ALPHA,AKT1m,PRKBA,CWS6,AKT
Approved Drugs1
Drugs in Clinical Trials24
Highest Development StageApproved

Akt1 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Strep Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
AK1-H5283
Human
HEK293
Human Akt1 Protein, His,Strep II Tag
Total: 1
  • 1

Akt1 Background

RAC-alpha serine/threonine-protein kinase (AKT1) is also known PKB, Protein kinase B alpha, PKB alpha, Proto-oncogene c-Akt and RAC-PK-alpha, which belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family and RAC subfamily and is expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase).

Akt1 Synonyms

AKT1,PKB,RAC,RAC-PK-alpha,PKB alpha

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AfuresertibGSK-2110183; GSK-2110183B; GSK-2110183C; GSK-21110183; LAE-002; LAE002; ASB-183Phase 3 ClinicalGlaxosmithkline Plc, Novartis Pharma AgAdenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
IpatasertibRG-7440; GCD-0068; GDC-0068; RO-5532961Phase 3 ClinicalArray Biopharma, Genentech IncAdenocarcinoma; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Head and Neck Neoplasms; Hepatic Insufficiency; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Mouth Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasm, Residual; Neoplasms; Neoplasms, Unknown Primary; Nose Neoplasms; Oropharyngeal Neoplasms; Ovarian Neoplasms; Paranasal Sinus Diseases; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urogenital Neoplasms
Details
NTQ-1062NTQ-1062; NTQ1062Phase 3 ClinicalNanjing Zhengda Tianqing Pharmaceutical Co LtdBreast Neoplasms; HR-positive breast cancer; Solid tumours
Details
SR-0379SR-0379Phase 3 ClinicalFunPep Co LtdSkin Ulcer
Details
Triciribine PhosphateNSC-154020; PTX-002; API-2; TCN-P; VQD-002-ORAL; VQD-002; NSC-280594; PTX-200Phase 2 ClinicalNational Cancer InstituteBreast Neoplasms; Hematologic Neoplasms; Leukemia; Neoplasms; Ovarian Neoplasms
Details
MiransertibMK-7075; ARQ-092Phase 2 ClinicalArqule IncEndometrial Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; PIK3CA-Related Overgrowth Spectrum; Proteus Infections; Proteus Syndrome; Solid tumours
Details
Ursolic AcidNSC-167406; NSC-4060Phase 2 ClinicalUniversity Of GuadalajaraBreast Neoplasms; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colonic Neoplasms; Colorectal Neoplasms; Insulin Resistance; Liver Neoplasms; Lung Neoplasms; Metabolic Syndrome; Muscular Atrophy; Pancreatic Neoplasms; Paraplegia; Prostatic Neoplasms; Quadriplegia; Sarcopenia; Spinal Cord Injuries; Stomach Neoplasms
Details
Uprosertib/Trametinib Dimethyl SulfoxidePhase 2 ClinicalNovartis Pharma AgEndometrial Neoplasms; Leukemia, Myeloid, Acute; Uterine Cervical Neoplasms
Details
Selumetinib sulfate/MK-2206Phase 2 ClinicalAstrazeneca Plc, Merck & Co IncAdenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rectal Neoplasms; Triple Negative Breast Neoplasms
Details
UprosertibGSK-2141795; GSK-2141795C; UPB-795; LAE-003; GSK-795Phase 2 ClinicalGlaxosmithkline Plc, National Cancer Institute, Novartis Pharma AgAdenocarcinoma, Clear Cell; Breast Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Melanoma; Multiple Myeloma; Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Uveal melanoma
Details
RX-0301RX-0201 nanoliposomal; RX-0201 Nano; HC0301; RX-0201-N; RX-0301; WGI-0301; RX-0201改良型Phase 2 ClinicalRexahn Pharmaceuticals IncCarcinoma, Hepatocellular; Liver Neoplasms
Details
TER-2013TER-2013Phase 2 ClinicalTerremoto Biosciences IncBreast Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms
Details
MK-2206MK2206; MK-2206; BIND-2206; NSC-749607Phase 2 ClinicalMerck Sharp & Dohme CorpAdenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Angioimmunoblastic T-cell Lymphoma; Bile Duct Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Lymphoma; Cholangiocarcinoma; Chronic eosinophilic leukemia (CEL); Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioma; Hodgkin Disease; Intraocular Lymphoma; Kidney Neoplasms; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Mast-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myelogenous,
Details
HZB-0071HZB-0071Phase 1 ClinicalHeilongjiang Zbd Pharmaceutical Co Ltd, Wuxi Apptec Co LtdNeoplasms
Details
RupitasertibDIACC3010; M-2698; MSC-2363318A; DIACC-3010Phase 1 ClinicalEmd Serono IncBreast Neoplasms; Glioblastoma; Solid tumours; Stomach Neoplasms
Details
CMX-2043LIP-EA; CMX-2043; R-LIP-EA-OHPhase 1 ClinicalIschemix LlcAngina, Unstable; Brain Injuries, Traumatic; Cardiovascular Diseases; Coronary Artery Disease; Non-ST Elevated Myocardial Infarction
Details
TER-1754TER-1754Phase 1 ClinicalTerremoto Biosciences IncTelangiectasia, Hereditary Hemorrhagic
Details
HonokiolPhase 1 ClinicalCarcinoma, Non-Small-Cell Lung; Gingival Diseases
Details
ATV-1601ATV-1601Phase 1 ClinicalAtavistik Bio IncBreast Diseases; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
ALTA-2618ALTA-2618Phase 1 ClinicalAlterome Therapeutics IncBreast Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours
Details
TQB-3912TQB3912; TQB-3912Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBreast Neoplasms; HR-positive breast cancer; Neoplasms; Prostatic Neoplasms
Details
Hu-7691Hu-7691Phase 1 ClinicalZhejiang UniversityNeoplasms; Solid tumours
Details
Oxysterols (Intsel Chimos)ClinicalCentre National De La Recherche Scientifique (Cnrs)Glioma
Details
AKT1 inhibitors(Atavistik Bio Inc)ClinicalAtavistik Bio IncTelangiectasia, Hereditary Hemorrhagic; Vascular Malformations
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
CapivasertibAZD-5363ApprovedAstex Pharmaceuticals Inc, Cancer Research Technology, The Institute Of Cancer Research, LondonTruqap, TRUQAP, 荃科得United StatesBreast NeoplasmsAstrazeneca Pharmaceuticals Lp2023-11-16Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hormone-Sensitive Prostate Neoplasms; HR-positive breast cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8